{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Pharmacokinetic albumin in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.","groups":[{"description":"Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \\>= 90 days at diagnosis and High Risk (HR) if age \\< 90 days at diagnosis.\n\nAsparaginase: Given IV, IM, or PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV or IT\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLestaurtinib: Given PO\n\nLeucovorin Calcium: Given IV\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IV, IT, or PO\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPharmacological Study: Correlative studies\n\nPrednisone: Given PO\n\nTherapeutic Hydrocortisone: Given IT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)"}],"populationDescription":"Data was and never will be collected","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks","title":"Pharmacokinetic Albumin in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy","type":"SECONDARY"}